Evexia Lifecare Ltd (EVEXIA) — shareholding pattern, promoter holding, financials and share price
About Evexia Lifecare Ltd (EVEXIA)
Evexia Lifecare Ltd operates in the Trading - Chemicals industry, within the Chemicals sector. It trades on the NSE as EVEXIA and on the BSE under scrip code 524444. Its ISIN is INE313M01030.
Incorporated in 1990, Evexia Lifecare Ltd does trading of Chemicals, Agriculture Produce and other Consumer Goods [1]
Evexia Lifecare Limited is engaged in the manufacturing and production of edible oils, agricultural products, and the trading of chemicals. It was originally involved in petrochemical downstream production.
The company operates a processing plant in Tundav, Gujarat, classified as a mini-refinery for processing crude oil and hydrocarbons into various products for industrial applications.
Listed peers in Trading - Chemicals: Vinyl Chemicals (I) Ltd, Dhariwalcorp Ltd, Bhavik Enterprises Ltd, A-1 Ltd, Shiv Texchem Ltd, Shankar Lal Rampal Dye-Chem Ltd.
Valuation & Returns
10 Jul 2026At ₹1.61 a share on 10 Jul 2026, Evexia Lifecare Ltd (EVEXIA) was valued at a price-to-earnings ratio of 146.01x against an industry P/E of 45.11x and a price-to-book of 2.34x on a book value of ₹0.69 per share as of Mar 2024. Solomo computes return on equity of 1.6% and return on capital employed of 0.33% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 146.01x
- Industry P/E
- 45.11x
- P/B
- 2.34x
- EPS (TTM)
- ₹0.01
- Book value / share
- ₹0.69
- ROE
- 1.6%
- ROCE
- 0.33%
- ROA
- 0.23%
- Debt / equity
- 5.3x
- Dividend yield
- 0%
- EBITDA margin
- 3.04%
- 52-week range
- ₹0.47 – ₹2.43
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Evexia Lifecare Ltd (EVEXIA) reported revenue of ₹110 crore, net profit of ₹2 crore and earnings per share of ₹0.01. That compares with revenue of ₹87 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹36.79 crore and net profit ₹0.78 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 76 | 70 | 56 | 87 | 110 |
| Net profit (₹ cr) | 1 | 1 | 1 | 0 | 2 |
| EPS (₹) | 0.01 | 0.01 | 0.02 | 0 | 0.01 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 10.57% | -2.95% | 5.41% | -19.09% |
| Profit growth | 18.27% | -26.86% | -3.15% | 105.97% |
| Stock price CAGR | 8% | -31% | -10% | -32% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 3.36% of Evexia Lifecare Ltd (EVEXIA) (down 0.13 pp QoQ), foreign institutional investors (FII) hold 0.12% and domestic institutional investors (DII) hold 0.1%. Market capitalisation was ₹302 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Mar 2026: Wave Capital Ltd 12.17%, Aio Growth Capital Fund Spc 8.5%, Nova Global Opportunities Fund Pcc - Touchstone 8.07%, Zeal Global Opportunities Fund 7.87%, M7 Global Fund Pcc - Cell Dewcap Fund 3.94%, Global Focus Fund 2.29%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 3.36% | - | 0.12% | 0.1% | 96.64% |
| Dec 2025 | 3.49% | - | 0.47% | 0.1% | 96.51% |
| Sep 2025 | 3.36% | - | 0.47% | 0.1% | 96.64% |
| Jun 2025 | 3.49% | - | - | 0.1% | 96.51% |
| Mar 2025 | 3.49% | - | 0.16% | 0.1% | 96.51% |
| Dec 2024 | 3.49% | - | 0.16% | 0.1% | 96.51% |
| Sep 2024 | 5.87% | - | 1.49% | 0.17% | 94.13% |
| Jun 2024 | 6.29% | 15.4% | 1.03% | 0.18% | 93.71% |